Clinical trialNCT04464980Active, not recruitingPhase 2Interventional

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

SponsorNYU Langone HealthEnrollment1,516Opioid Use Disorder (OUD)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Edward V Nunes, MD
New York State Psychiatric Institute/Columbia University Irving Medical Center
Principal Investigator
clinicaltrials.gov ↗
John Rotrosen, MD
NYU Langone Health
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Roger Weiss, MD
Harvard Medical School/McLean Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arkansas for Medical Sciences (uams) / Center for Addiction Services and Treatment (cast)
Little Rock, Arkansas, United States
Tarzana Treatment Centers, Inc.
Tarzana, California, United States
Liberation Programs, Inc.
Bridgeport, Connecticut, United States
Operation Par
Clearwater, Florida, United States
Gateway Community Services
Jacksonville, Florida, United States
Aspire Health Partners
Orlando, Florida, United States
Mountain Manor / Maryland Treatment Centers
Baltimore, Maryland, United States
Mclean Hospital
Belmont, Massachusetts, United States
Stanley Street Treatment and Resources, Inc.
Fall River, Massachusetts, United States
Square Medical Group, Llc
Newton, Massachusetts, United States
Gibson Center for Behavioral Change
Cape Girardeau, Missouri, United States
Dartmouth Hitchcock - Atp
Lebanon, New Hampshire, United States
University of New Mexico Addiction and Substance Abuse Program
Albuquerque, New Mexico, United States
Bellevue Hospital Center
New York, New York, United States
Adapt Integrated Health Care
Roseburg, Oregon, United States
Adapt Integrated Health Care
Winston, Oregon, United States
Center for Psychiatric and Chemical Dependency Services (cpcds)
Pittsburgh, Pennsylvania, United States
Internal Medicine Recovery Engagement Program (im-Rep)
Pittsburgh, Pennsylvania, United States
Shoreline Behavioral Health Services
Conway, South Carolina, United States
Huntsman Mental Health Institute / University of Utah
Salt Lake City, Utah, United States
Chestnut Ridge Center
Morgantown, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SL-BUPXR-BUPXR-NTX

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jun 2021
Primary completion: 31 Dec 2026
Completion: 31 Jan 2027
Last update posted: 21 Jul 2026
Registered enrollment: 1,516
Registry id: NCT04464980

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.